Beta-lactam and Beta-lactamase Inhibitors Market Overview
The Beta-lactam and Beta-lactamase Inhibitors Market size is estimated to reach $31,271 million by 2027. Furthermore, it is poised to grow at a CAGR of 2.3% over the forecast period of 2022-2027. Beta-lactamase inhibitors are antibiotics that prevent the breakdown of beta-lactam antibiotics by blocking the activity of beta-lactamase enzymes (also known as beta-lactamases). On their alone, they don't have a lot of antimicrobial activity. Certain strains of the bacteria such as Bacteroides species, Enterococcus species, Hemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, and Staphylococcus species produce beta-lactamase enzymes either naturally or in response to antimicrobials. Beta-lactamases inactivate antibiotics by cleaving the beta-lactam ring of susceptible penicillins and cephalosporins. Certain antibiotics (such as cefazolin and cloxacillin) are naturally resistant to beta-lactamases. By combining beta-lactams with a beta-lactamase inhibitor, the action of amoxicillin, ampicillin, piperacillin, and ticarcillin can be restored and widened. Clavulanic acid is a -lactamase inhibitor that is used in combination with -lactam antibiotics to combat resistance to them. Sulbactam is an irreversible, competitive beta-lactamase inhibitor. It has a limited intrinsic antibacterial action owing to its binding to penicillin-binding proteins. Sulbactam's synergy with beta-lactam antibiotics is most noticeable in bacteria with beta-lactamase as a critical resistance mechanism. Piperacillin-tazobactam is a beta-lactam/beta-lactamase inhibitor with antibacterial efficacy against Gram-positive and Gram-negative aerobic and anaerobic bacteria. Monobactams are antibiotics that only have the -lactam moiety and are solely active against Gram-negative bacteria. They are inactive against Gram-positive bacteria.
The rising prevalence of infectious diseases and growing advancement in the medical sector are factors driving the Beta-lactam and Beta-lactamase Inhibitors Industry forward in the forecast period of 2022-2027.
Beta-lactam and Beta-lactamase Inhibitors Market Report Coverage
The report: “Beta-lactam and Beta-lactamase Inhibitors Market Forecast (2022-2027)" by Industry ARC covers an in-depth analysis of the following segments of the Beta-lactam and Beta-lactamase Inhibitors Market.
- Geographically, in 2021 North America held a dominant market share. It is owing to the surging advancement in the healthcare sector that expands the development of various types of drugs which in turn enhances the growth of beta-lactam and beta-lactamase inhibitors. Every year, the U.S. pharmaceutical industry develops various new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Private spending on pharmaceutical R&D and the approval of new drugs have increased in recent years, which further surges the demand for beta-lactamase inhibitor drugs. Moreover, an increasing number of diseases such as respiratory infection, skin infection, and many more further surges the demand for the beta-lactamase inhibitor market.
- The rising prevalence of infectious diseases and growing advancement in the medical sector are driving the Beta-lactam and Beta-lactamase Inhibitors Market. However, the rising cost of drugs is one of the factors impeding the market growth.
- A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Beta-lactam and Beta-lactamase Inhibitors Market Report.
Beta-lactam and Beta-lactamase Inhibitors Market- Geography (%) for 2021.
For More Details on This Report - Request for Sample
Beta-lactam and Beta-lactamase Inhibitors Market Segmentation Analysis- By Drug Class
The Beta-lactam and Beta-lactamase Inhibitors market based on drug class can be further segmented into Penicillin, Cephalosporin, Carbapenem, Monobactum, and Combination. Penicillin held a dominant market share in the year 2021. Penicillin antibiotics treat ear infections, sinus infections, urinary tract infections, lower respiratory infections, and pneumonia. Penicillin prevents germs from growing, and the beta-lactamase inhibitor shields the antibiotic from bacteria, boosting its effectiveness. Penicillin is available primarily in an oral combination with a beta-lactamase inhibitor which is amoxicillin-clavulanate. This combination drug provides antimicrobial coverage of beta-lactamase-producing strains of S. aureus, H. influenzae, N. gonorrhea, E. coli, M. catarrhalis, and Proteus, Klebsiella, and Bacteroides species. It has little activity against Pseudomonas or methicillin-resistant S. aureus.
However, Cephalosporin is estimated to be the fastest-growing, with a CAGR of 3.9% over the forecast period of 2022-2027. Cephalosporin beta-lactamase inhibitor combinations treat complicated bacterial infections like intra-abdominal and urinary tract infections. The cephalosporin antibiotic prevents the growth of the bacteria, and the beta-lactamase inhibitor protects the antibiotic from the bacteria, increasing its effectiveness. Cephalosporins are an antibiotic used to treat a range of bacterial infections. There are different generations of cephalosporins, and some are better suited to treat certain infections than others.
Beta-lactam and Beta-lactamase Inhibitors Market Segmentation Analysis- By Route of Administration
The Beta-lactam and Beta-lactamase Inhibitors market, based on the Route of Administration, can be further segmented into Oral, Intravenous, and Others. Oral held a dominant market share in the year 2021. It is owing to the majority of beta-lactam being used orally. Orally administered beta-lactam drugs such as amoxicillin and ampicillin are used primarily to treat mild infections such as otitis media, sinusitis, bronchitis, urinary tract infections, and bacterial diarrhea. Amoxicillin is the agent of choice for the treatment of otitis media. Combinations of -lactam/-lactamase inhibitors are generally well-tolerated, and their oral versions enable efficient outpatient treatment for various illnesses. In some cases, they can be less expensive than traditional combo therapy.
However, Intravenous is estimated to be the fastest-growing, with a CAGR of 3.4% over the forecast period of 2022-2027. It is owing to the rising availability of drugs in intravenous forms as it helps to reduce the diseases rapidly. Various types of intravenous beta-lactam drugs, including Avycaz and many others, are approved by the US Food and Drug Administration (FDA) to treat complicated infections. It contains a third-generation cephalosporin beta-lactam antibacterial ceftazidime and a new beta-lactamase inhibitor, avibactam. Intravenous beta-lactam inhibitor is also used to treat a variety of diseases which in turn increases its demand in the healthcare sector.
Beta-lactam and Beta-lactamase Inhibitors Market Segmentation Analysis- By Geography
The Beta-lactam and Beta-lactamase Inhibitors market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. In 2021, North America held a dominant market share of 47% compared to its other counterparts. The development of various sorts of medications has increased owing to the rapid improvement in the healthcare industry, which has boosted the expansion of beta-lactam and beta-lactamase inhibitors. Every year, the pharmaceutical industry in the United States generates a wide range of new pharmaceuticals with significant medical benefits. Many of these drugs are costly, contributing to increased healthcare expenses in the private and public sectors. Private spending on pharmaceutical research and development, as well as the approval of new treatments, has risen dramatically in recent years, boosting demand for beta-lactamase inhibitors even more. Furthermore, an increase in the number of diseases such as lung infection, skin infection, and others is driving up demand for beta-lactamase inhibitors. According to the National Institute of Health, more than 25 million people suffer from respiratory diseases, which roses the demand for beta-lactam inhibitors and thus escalates the market growth.
Beta-lactam and Beta-lactamase Inhibitors Market Drivers
The Rising Prevalence of Infectious Diseases Surges the Demand for Beta-lactam inhibitor drugs that have Readily Aided the Market Growth.
The -lactam class of antimicrobial agents has played a critical role in treating infectious diseases, but –lactamases (enzymes produced by bacteria that can hydrolyze the -lactam core of the antibiotic) have posed an ever-increasing threat to their continued use. As a result, infections caused by organisms that only produce one penicillinase can be easily treated with a -lactamase inhibitor combination like amoxicillin-clavulanic acid, ampicillin-sulbactam, or piperacillin-tazobactam. The lactams are well tolerated, efficacious, and widely prescribed. Their central toxicity is related to an allergic response in a small percentage of patients who react to related side-chain determinants; notably, these reactions are most familiar with penicillins and cephalosporins with minimal reactivity caused by Monobactams. The bactericidal killing mechanism of lactams is a significant advantage in treating severe infections. When these agents were threatened by the rapid emergence of -lactamases, lactamase-stable agents were developed, as well as potent lactamase inhibitors (BLIS). Lactam antibiotics are efficacious and are superior to other antibiotic classes for a variety of infections, including those caused by carbapenem-resistant Enterobacterales (CRE) and methicillin-susceptible Staphylococcus aureus (MSSA). According to the Centers for Disease Control and Prevention, about 3.4 million people have infectious diseases in 2019, which gives rise to the demand for the beta-lactam and beta-lactamase inhibitors market.
Growing Advancement in the Medical Sector Gives Rise to the Demand for Beta-lactam and Beta-lactamase Inhibitors Market.
The health industry is growing rapidly. As technology advances, the medical industry has benefitted more than any other. The advancements in technology are revolutionizing the healthcare system to become more proactive, personalized, and convenient. Recently, the pharma industry has been overgrowing and is invested in many R&D expenditures where expenditures cover a variety of activities, including discovering and testing new drugs, developing incremental innovations such as product extensions, and clinical testing for safety-monitoring or marketing purposes. The number of new drugs approved each year has also grown. The Food and Drug Administration (FDA) approved 38 categories of new drugs, 60% more than the yearly average in 2019. A growing list of vendors provides specialist support in manufacturing, sales, patient services, and pharmacovigilance. Owing to the growing medical sector, the development of drugs also surges which further escalates the market growth.
Beta-lactam and Beta-lactamase Inhibitors Market Challenges
The Rising Cost of Drugs is the key factor impeding the market growth.
The pharmaceutical industry develops various new drugs now and then that provide valuable medical benefits, which are primarily expensive owing to the year-on-year hike by key brands that hold the patents. This contributes to rising health care costs for the private sector and the federal government. Developing new drugs is a costly and uncertain process. Only about 12 percent of drugs entering clinical trials are ultimately approved for introduction by the FDA. According to the Food and Drug Administration, the average R&D cost per new drug range from less than $1 billion to more than $2 billion per drug. Those estimates include the costs of both laboratory research and clinical trials of successful new drugs and expenditures on drugs. The development process often takes a decade or more, and during that time, the company does not receive a financial return on its investment in developing that drug. New drugs have almost always come with a higher price to help offset the cost of their research and development.
Beta-lactam and Beta-lactamase Inhibitors Industry Outlook
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Beta-lactam and Beta-lactamase Inhibitors Market. The top 10- Beta-lactam and Beta-lactamase Inhibitors Market companies are-
- Centrient Pharmaceuticals
- Arixa Pharmaceuticals
- Abbott laboratories
- Pfizer Inc.
- Novartis AG
- GlaxoSmithKline plc
- Teva Pharmaceuticals
- Merck KGaA
- In April 2022, QPEX Biopharma announced the result of clinical data from Ultra-Broad Spectrum Beta-Lactamase Inhibitor Xeruborbactam and the Lipopeptide QPX9003. These agents represent new potential therapies for patients with drug-resistant infections – notably carbapenem-resistant Acinetobacter, Pseudomonas, and Enterobacterales, for which the World Health Organization (WHO) has identified as in critical need of new treatments. The Phase 1 clinical studies were conducted as part of Qpex’s partnership with the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA).
- In April 2022, Zerbaxa was approved by US FDA for Complicated Paediatric Intra-Abdominal and Urinary Tract Infections. The medicine combines ceftolozane, a cephalosporin antibacterial, and tazobactam, a beta-lactamase inhibitor. Pediatric approval was based on data from randomized, active comparator-controlled, double-blind studies. The most common adverse reactions reported in pediatric patients were thrombocytosis, diarrhea, pyrexia, leukopenia, abdominal pain, vomiting, increased aspartate aminotransferase, and anemia.
- In September 2021, Centrient Pharmaceuticals acquired Astral SteriTech to strengthen its position as a global business in beta-lactam antibiotics. With the help of this acquisition, the product portfolio expanded, which helped to meet the needs of customers.
Report Code- HCR 0709
Report Code- HCR 0075
Report Code-HCR 0149
For more Lifesciences and Healthcare Market reports, please click here